Germany-based healthcare investor SHS Capital is acquiring a majority stake in Basic Pharma, a Dutch speciality pharmaceutical platform and full-service CDMO, providing a succession solution for the founder and in support of developing Basic Pharma into a leading European speciality pharma and dossier development platform for nasal sprays.
Founded in 2003 by pharmacist Bob Kool, Basic Pharma has evolved from a local contract manufacturer into an integrated pharmaceutical platform combining in-house product development, regulatory affairs, pharmacovigilance and GMP manufacturing. It serves an international client base across prescription (Rx) and over-the-counter (OTC) pharmaceuticals as well as investigational medicinal products. Today Basic Pharma employs around 250 people.
The firm is differentiated by its ability to develop, register and out-license product dossiers. Under its “licence & supply” model, internally developed products are licensed to distributors and pharmaceutical partners while Basic Pharma retains exclusive manufacturing and market authorisation rights, creating long-term customer relationships and strong recurring revenues.
“Basic Pharma is . . . a specialised European healthcare champion with a differentiated business model, proprietary dossiers and significant untapped international potential,” said Dr Cornelius Maas, partner at SHS Capital. “We look forward to supporting the team in the next phase of growth, organically and through selective acquisitions.”
With SHS Capital, Basic Pharma will strengthen its core business, drive operational excellence, further professionalise the organisation and accelerate international expansion, particularly in European markets. The firm is also well positioned as a platform for selective buy-and-build opportunities in the fragmented European CDMO landscape.
The transaction marks the end of the involvement of Brightlands Venture Partners (BVP), Particon and co-founder Jacques Havermans as shareholders. BVP invested in 2005 and Particon joined in 2011.
Kool will remain a shareholder and member of the advisory board.
“It was very important to me to place the succession of my life’s work in the right hands. With SHS, we have found a highly experienced and specialised healthcare private equity fund that truly understands our business, values our people and shares our ambitions,” said Kool.
